LUCD Stock Latest News

Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion

PremiumCompany Announcements

8d ago

Lucid Diagnostics Reports Revenue Growth and Secures Funding

PremiumCompany Announcements

8d ago

Lucid Diagnostics reports Q3 adjusted EPS (20c), consensus (22c)

PremiumThe Fly

8d ago

Lucid Diagnostics Announces Convertible Notes Exchange Initiative

PremiumCompany Announcements

9d ago

PremiumPre-EarningsLUCD Earnings Report this Week: Is It a Buy, Ahead of Earnings?

13d ago

Lucid Diagnostics granted patent underlying its EsoGuard Esophageal DNA Ttest

The Fly

Lucid Diagnostics granted patent underlying its EsoGuard Esophageal DNA Ttest

1M ago

Castle Biosciences price target raised to $40 from $35 at BTIG

The Fly

Castle Biosciences price target raised to $40 from $35 at BTIG

1M ago

CSTL

Lucid Diagnostics management to meet virtually with BTIG

PremiumThe Fly

2M ago

PAVmed announces efforts to regain Nasdaq compliance

PremiumThe Fly

2M ago

Lucid Diagnostics partnering with Front Line Mobile Health in esophageal cancer

PremiumThe Fly

3M ago

Lucid Diagnostics’ EsoGuard cancer diagnosis test highlighted in publication

PremiumThe Fly

3M ago

PremiumCompany AnnouncementsLucid Diagnostics Unveils Key Unfiled Financial Snapshot

3M ago

Lucid Diagnostics reports Q2 EPS (20c), consensus (22c)

The Fly

Lucid Diagnostics reports Q2 EPS (20c), consensus (22c)

3M ago

Lucid Diagnostics’ EsoGuard esophageal precancer testing shows efficacy

The Fly

Lucid Diagnostics’ EsoGuard esophageal precancer testing shows efficacy

4M ago

Lucid Diagnostics announces record quarterly EsoGuard test volume

PremiumThe Fly

4M ago

Lucid Diagnostics announces data from ESOGUARD BE-1 study of EsoGuard

PremiumThe Fly

5M ago

Lucid Diagnostics files to sell 72.36M shares of common stock for holders

PremiumThe Fly

5M ago

Lucid Diagnostics Insights: Performance and Outlook Update

PremiumCompany Announcements

6M ago

PremiumThe FlyLucid Diagnostics reports Q1 non-GAAP EPS (21c), consensus (27c)

6M ago

Lucid SOS esophageal cell collection device subject to Class II FDA recall

The Fly

Lucid SOS esophageal cell collection device subject to Class II FDA recall

7M ago

Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale

Company Announcements

Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale

7M ago